Latest Breaking News On - Frontier medicines - Page 5 : comparemela.com
- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56
- Delivers Full-Year Net Revenues of $45.804 Billion on a GAAP Basis, an Increase of 37.7 Percent on a Reported Basis; Adjusted Net Revenues Were $45.784 Billion
- Full-Year Global Net Revenues from the Immunology Portfolio Were $22.153 Billion, an Increase of 13.2 Percent on a Reported Basis, or 13.4 Percent on an Operational Basis; U.S. Humira Net Revenues Were $16.112 Billion, an Increase of 8.4 Percent; Internationally, Humira Net Revenues Were $3.720 Billion, a Decrease of 13.6 Percent on a Reported Basis, or 12.5 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.590 Billion; Global Rinvoq Net Revenues Were $731 Million
United-statesAmericanAlphagan-combiganLinzess-constellaRicharda-gonzalezLumigan-ganfortOrilissa-oriahnnJanssen-biotech-incAmerican-society-of-hematology-annual-meetingLinkedinGenentechTwitterShare this article
Share this article
SOUTH SAN FRANCISCO, Jan. 8, 2021 /PRNewswire/ Frontier Medicines, Corp., a precision medicine company drugging challenging protein targets to develop breakthrough medicines that change the course of human diseases, today announced that Chris Varma, Ph.D., Frontier s co-founder, chairman, and CEO, will present a webcasted company overview at the 39
th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 2:35 p.m. ET.
A live audio webcast of the presentation will be available for access in the News & Media section of Frontier s website at https://frontiermeds.com/latest-news#presentations. An archived replay will be accessible for 30 days following the event.
Chris-varmaLinkedinHealthcare-conferenceFrontier-medicinesகிறிஸ்-வர்மாசென்டர்சுகாதாரம்-மாநாடுஎல்லை-மருந்துகள்